ConnexPay launches revolutionary real-time B2B payments in Europe with GBP, EUR currencies
18.7.2023 14:00:00 EEST | Business Wire | Press release
ConnexPay, the first and only payments technology company that offers a fully integrated payments acceptance and payment issuance solution inside a single platform, has expanded upon an already impressive global footprint with the launch of British Pounds (GBP) and Euros (EUR) currencies. The company has operated for years in the European market, but this release allows European companies the flexibility to receive and send payments in their native currencies.
Despite the complexity of the payments landscape, ConnexPay’s core solution is extremely smart and user-friendly. The all-in-one platform allows merchants to have immediate access to incoming customer payments, which they can then use in real time to fund virtual cards to pay suppliers. With ConnexPay, businesses no longer have to wait for incoming payments to clear before accessing those funds, a process that could take anywhere from days to weeks, causing cashflow problems for a company’s entire supply chain. In addition, ConnexPay’s payments solution integrates fraud prevention and chargeback management plus a fully-featured reporting and analytics suite – all inside a single platform with one contract, one reconciliation, and one team.
The company already has a number of international customers who now add the ability to transact in GBP and EUR. Enabling them to issue in multiple currencies globally is vital to these businesses, and there are a host of additional global companies that will be implementing ConnexPay’s solution and going live this month.
Bob Kaufman, Founder and CEO at ConnexPay, said: “After five years building our solution to great success in North America, we’re excited to launch native currencies in Europe knowing that our solution is fit for purpose, global in scope and simply connects payments. We have worked closely with our key partners to ensure that what we are delivering is exactly what the market needs. ConnexPay is the only company in the world that provides an end-to-end payments solution all inside a single platform.”
He added: “We have shown our international customers that having both card issuing and acceptance as a single solution can significantly increase efficiencies and lower the costs of both accepting incoming payments and making cross-border payments. I’m thrilled to already have some innovative customers on board with the ability to issue in more currencies, helping these companies scale, as we scale, and continuing to work with them to bring their services to customers across the globe.”
ConnexPay currently processes billions in volume and recently received a $110 million growth equity investment led by FTV Capital, a sector-focused investor with more than two decades of experience in payments and financial services. The investment from FTV Capital has been a major factor in enabling ConnexPay to expand globally with a revolutionary product and the infrastructure to support rapid growth. In the last 12 months alone, ConnexPay has seen revenue increase by 500% and expects to double revenue this year.
To learn more visit: https://connexpay.com/
About ConnexPay
ConnexPay is the first and only company to bring together the two sides of the payment process — payments acceptance and virtual payments issuing — into a single platform with one contract and one reconciliation. The flexibility of this technology allows clients to adopt the full end-to-end acquiring and issuing solution or leverage ConnexPay’s innovative intelligent routing issuing-only platform.
Although ConnexPay started its journey with a focus on the travel and tourism space, ConnexPay’s solutions are applicable across a broad spectrum of corporate payment use cases. The platform is well suited for corporate disbursements like insurance and warranty claims, loyalty and rewards payouts as well as corporate procurements like media/advertising buys and ticketing.
The company’s technology simplifies an antiquated workflow, eliminates the need for pre-funded accounts, reduces supplier risk and the cost of accepting card payments while safeguarding consumer spend. Learn more at www.connexpay.com and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718177919/en/
Contact information
Ben Redman, SkyParlour
ben@skyparlour.com
+44 (0)330 043 1315
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom